Cureus has published a narrative review of polydeoxyribonucleotide (PDRN) for post-procedure recovery in aesthetic medicine. The review treats the compound as a regenerative adjunct rather than a primary intervention.

PDRN has circulated in regenerative medicine for several decades. The compound most often appears as a low-molecular-weight DNA preparation extracted from salmon or trout gonads. Its mechanistic claim centers on adenosine A2A receptor agonism, the activation of cell-surface proteins that modulate inflammation and downstream fibroblast activity.

In aesthetic aftercare, those fibroblasts drive collagen deposition and extracellular-matrix regeneration (the supporting scaffold surrounding dermal cells). The Cureus synthesis applies that biology to recovery after laser resurfacing, chemical peels, microneedling, and radiofrequency treatments.

What breadth of post-procedure indications does the review address?

A separate caveat concerns the procedural range under review. Aesthetic medicine spans ablative and non-ablative lasers, deep chemical peels, platelet-rich plasma combined with microneedling, and fractional radiofrequency with microneedling. Each modality injures the skin to a different degree and demands different recovery benchmarks.

A coherent narrative review must address that procedural heterogeneity rather than collapse it. Without the full text, this reviewer cannot confirm whether the Cureus authors stratified their evidence by procedure depth or pooled outcomes across modalities.

What does the Cureus paper actually cover?

The source documents only the title and publication venue. Readers cannot verify the exact inclusion criteria, search dates, number of included primary studies, or reported effect sizes from this feed. Readers should treat the review as a curated expert overview rather than a quantitative evidence grade.

Heterogeneity in the underlying trials will likely reflect differences in PDRN concentration, vehicle formulation, treatment schedule, and comparator choice.

Why does the narrative-review designation matter?

That distinction matters procedurally. Narrative reviews lack the structured search strings, dual independent screening, or risk-of-bias scoring that define systematic reviews. They permit authors to integrate mechanistic reasoning, clinical anecdote, and heterogeneous trials in a way systematic reviews typically exclude.

Reproducibility suffers: a reader cannot reconstruct the evidence base from the text alone, and that gap deserves flagging before any downstream clinical claim.

How does PDRN fit into existing aftercare?

Standard aesthetic aftercare already includes petrolatum-based occlusives, topical corticosteroids, and growth-factor serums. PDRN enters that space as a polynucleotide-class alternative with proposed advantages in receptor specificity.

Its tolerability record reportedly avoids the telangiectasia (visible small-vessel dilation) sometimes associated with prolonged steroid use. Whether those theoretical gains translate into measurable reductions in erythema duration, transepidermal water loss (a quantitative measure of skin-barrier permeability), or time to re-epithelialization (regrowth of the outer skin layer) remains an empirical question the review presumably addresses.

What regulatory caveat should clinicians note?

The FDA has not approved PDRN as an injectable in the United States. Practitioners, however, widely compound and use the preparation in Korean and Italian aesthetic practice, where regulators have cleared it as a device or biologic.

That regulatory asymmetry caps the practical reach of any clinical recommendation drawn from a narrative review of this scope. Off-label access in the U.S. depends on pharmacy compounding rather than an on-label indication, and reimbursement coding for compounded injectables adds a further access layer that U.S. dermatologists must navigate.

What should readers watch next?

Larger randomized controlled trials with standardized PDRN concentrations and blinded outcome assessors are the obvious next step. Active comparators against petrolatum or standard emollients would sharpen the comparative-effectiveness case.

Until those arrive, the Cureus review functions as a map of the question rather than a verdict on it. Its value lies in organizing the literature, not in closing the case for clinical adoption.